These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 15917644)
1. Proteasome inhibitors in cancer therapy. Orlowski RZ Methods Mol Biol; 2005; 301():339-50. PubMed ID: 15917644 [TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition for treatment of multiple myeloma: clinical update. Stadtmauer EA J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib and its role in the management of patients with multiple myeloma. Orlowski RZ Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218 [TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition: a new approach for the treatment of malignancies. Spano JP; Bay JO; Blay JY; Rixe O Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib: a novel therapy approved for multiple myeloma. Richardson PG; Anderson KC Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456 [TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954 [TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition as a novel therapeutic target in human cancer. Rajkumar SV; Richardson PG; Hideshima T; Anderson KC J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509 [TBL] [Abstract][Full Text] [Related]
14. The persisting challenge of selective and specific proteasome inhibition. Groll M; Huber R; Moroder L J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822 [TBL] [Abstract][Full Text] [Related]
15. The role of proteasome in malignant diseases. Moran E; Nencioni A J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285 [TBL] [Abstract][Full Text] [Related]
17. [Proteasome inhibitors]. Hatake K; Mishima Y; Terui Y Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575 [TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors in pediatric cancer treatment. Bachmann AS Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901 [TBL] [Abstract][Full Text] [Related]